Mostrar el registro sencillo del ítem

dc.contributor.authorVillar-Alvarez, E
dc.contributor.authorCambon, A
dc.contributor.authorPardo, A
dc.contributor.authorArellano, L
dc.contributor.authorMarcos, A V
dc.contributor.authorPelaz, B
dc.contributor.authorDel Pino, P
dc.contributor.authorBouzas Mosquera, Alberto 
dc.contributor.authorMosquera Rodríguez, Victor X 
dc.contributor.authorAlmodlej, A
dc.contributor.authorPrieto, G
dc.contributor.authorBarbosa, S
dc.contributor.authorTaboada, P
dc.date.accessioned2022-01-25T12:16:01Z
dc.date.available2022-01-25T12:16:01Z
dc.date.issued2019
dc.identifier.issn1477-3155
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/31615570es
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794818/pdf/12951_2019_Article_538.pdfes
dc.identifier.urihttp://hdl.handle.net/20.500.11940/15903
dc.description.abstractBACKGROUND: Improving the water solubility of hydrophobic drugs, increasing their accumulation in tumor tissue and allowing their simultaneous action by different pathways are essential issues for a successful chemotherapeutic activity in cancer treatment. Considering potential clinical application in the future, it will be promising to achieve such purposes by developing new biocompatible hybrid nanocarriers with multimodal therapeutic activity. RESULTS: We designed and characterised a hybrid nanocarrier based on human serum albumin/chitosan nanoparticles (HSA/chitosan NPs) able to encapsulate free docetaxel (DTX) and doxorubicin-modified gold nanorods (DOXO-GNRs) to simultaneously exploit the complementary chemotherapeutic activities of both antineoplasic compounds together with the plasmonic optical properties of the embedded GNRs for plasmonic-based photothermal therapy (PPTT). DOXO was assembled onto GNR surfaces following a layer-by-layer (LbL) coating strategy, which allowed to partially control its release quasi-independently release regarding DTX under the use of near infrared (NIR)-light laser stimulation of GNRs. In vitro cytotoxicity experiments using triple negative breast MDA-MB-231 cancer cells showed that the developed dual drug encapsulation approach produces a strong synergistic toxic effect to tumoral cells compared to the administration of the combined free drugs; additionally, PPTT enhances the cytostatic efficacy allowing cell toxicities close to 90% after a single low irradiation dose and keeping apoptosis as the main cell death mechanism. CONCLUSIONS: This work demonstrates that by means of a rational design, a single hybrid nanoconstruct can simultaneously supply complementary therapeutic strategies to treat tumors and, in particular, metastatic breast cancers with good results making use of its stimuli-responsiveness as well as its inherent physico-chemical properties.en
dc.language.isoenges
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshDelayed-Action Preparations*
dc.subject.meshTriple Negative Breast Neoplasms*
dc.subject.meshGold*
dc.subject.meshPhototherapy*
dc.subject.meshCell Line*
dc.subject.meshDoxorubicin*
dc.subject.meshLight*
dc.subject.meshNanotubes*
dc.subject.meshSerum Albumin*
dc.subject.meshPhotochemotherapy*
dc.subject.meshNanocapsules*
dc.subject.meshAntineoplastic Agents*
dc.titleCombination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsulesen
dc.typeArtigoes
dc.identifier.doi10.1186/s12951-019-0538-3 [pii]
dc.identifier.pmid31615570
dc.identifier.sophos32287
dc.issue.number1es
dc.journal.titleJournal of Nanobiotechnologyes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de A Coruña - Complexo Hospitalario Universitario de A Coruña:: Cirurxía Cardíacaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Biomédica da Coruña (INIBIC)es
dc.rights.accessRightsopenAccesses
dc.subject.decsalbúmina sérica*
dc.subject.decspreparaciones de acción retardada*
dc.subject.decsneoplasias de mama triple negativos*
dc.subject.decsnanocápsulas*
dc.subject.decsnanotubos*
dc.subject.decslínea celular*
dc.subject.decsfotoquimioterapia*
dc.subject.decsdoxorrubicina*
dc.subject.decsluz*
dc.subject.decsoro*
dc.subject.decsfototerapia*
dc.subject.decsantineoplásicos*
dc.subject.keywordCHUACes
dc.subject.keywordINIBICes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number17es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional